

SNCA gene

synuclein alpha

Normal Function

The *SNCA* gene provides instructions for making a small protein called alpha-synuclein. Alpha-synuclein is abundant in the brain, and smaller amounts are found in the heart, muscles, and other tissues. In the brain, alpha-synuclein is found mainly at the tips of nerve cells (neurons) in specialized structures called presynaptic terminals. Presynaptic terminals release chemical messengers, called neurotransmitters, from compartments known as synaptic vesicles. The release of neurotransmitters relays signals between neurons and is critical for normal brain function.

Although the function of alpha-synuclein is not well understood, studies suggest that it plays an important role in maintaining an adequate supply of synaptic vesicles in presynaptic terminals. It may also help regulate the release of dopamine, a neurotransmitter that is critical for controlling the start and stop of voluntary and involuntary movements. Alpha-synuclein may also play a role in the movement of structures called microtubules that help cells maintain their shape.

Health Conditions Related to Genetic Changes

Multiple system atrophy

Several common variations in the *SNCA* gene have been found to increase the risk of multiple system atrophy, a progressive brain disorder that affects movement and balance and disrupts the function of the autonomic nervous system. The autonomic nervous system controls actions that are mostly involuntary, such as regulation of blood pressure.

The identified gene variations each change a single DNA building block (nucleotide) in the *SNCA* gene. Researchers are working to determine whether these changes alter the function of alpha-synuclein and how they influence the risk of developing multiple system atrophy. Variations in the *SNCA* gene appear to affect disease risk in people of European descent; however, studies suggest that changes in this gene are not associated with multiple system atrophy in the Chinese population or in South Koreans. It is unclear whether *SNCA* gene variations are a risk factor for this condition in people of other geographic and ethnic backgrounds.

Dementia with Lewy bodies

At least six mutations in the *SNCA* gene have been found to cause dementia with Lewy bodies. This condition is characterized by intellectual decline (dementia); visual hallucinations; sudden changes in attention and mood; and movement problems characteristic of Parkinson's disease (described below) such as rigidity of limbs, tremors, and impaired balance and coordination. A characteristic feature of this condition is Lewy bodies, which are abnormal clusters of alpha-synuclein protein in the brain. Lewy bodies also occur in Parkinson's disease, but they tend to be more widespread in the brain in dementia with Lewy bodies.

In dementia with Lewy bodies, *SNCA* gene mutations lead to the production of an alpha-synuclein protein with an abnormal shape. The misshapen proteins cluster together, forming the main component of Lewy bodies. These protein clusters are present throughout the brain where they impair neuron function and ultimately cause cell death. Over time, the loss of neurons increasingly impairs intellectual and motor function and the regulation of emotions, resulting in the signs and symptoms of dementia with Lewy bodies.

Parkinson's disease

At least 30 mutations in the *SNCA* gene have been found to cause Parkinson's disease, a condition characterized by progressive problems with movement and balance. *SNCA* gene mutations are associated with the early-onset form of the disorder, which typically appears before age 50. Other variations in the *SNCA* gene have been found to increase the risk of developing Parkinson's disease, although they do not appear to be a direct cause of the disease.

Researchers have described two types of alterations of the *SNCA* gene in people with Parkinson's disease. One type changes single protein building blocks (amino acids) used to make alpha-synuclein. In some cases, the amino acid alanine is replaced with the amino acid threonine at protein position 53 (written as Ala53Thr or A53T) or with the amino acid proline at position 30 (written as Ala30Pro or A30P). These alterations cause the alpha-synuclein protein to take on an incorrect 3-dimensional shape (misfold). In the other type of alteration, one of the two *SNCA* genes in each cell is inappropriately duplicated or triplicated. The extra copies of the *SNCA* gene lead to an excess of alpha-synuclein protein.

It is unclear how alterations in the *SNCA* gene cause Parkinson's disease. This condition involves the selective death or impairment of neurons that produce dopamine. Misfolded or excess alpha-synuclein proteins may cluster together to form Lewy bodies and impair the function of these neurons in specific regions of the brain. Lewy bodies may disrupt the regulation of dopamine, which allows dopamine to accumulate to toxic levels and eventually kill neurons. Researchers also suspect that Lewy bodies stall or shut down the cell machinery that removes unneeded proteins. As a result, unneeded proteins may clog neurons and impair their functions. Symptoms of Parkinson's disease appear when dopamine-producing neurons become impaired or die. The loss of these cells weakens communication between the brain and muscles, and ultimately the brain

becomes unable to control muscle movement. The presence of Lewy bodies in a region of the brain called the substantia nigra, which controls balance and movement, are a characteristic feature of Parkinson's disease.

Other Names for This Gene

- alpha-synuclein
- NACP
- nonA-beta component of AD amyloid
- PARK1
- PARK4
- PD1
- synuclein, alpha (non A4 component of amyloid precursor)
- SYUA_HUMAN

Additional Information & Resources

Tests Listed in the Genetic Testing Registry

- Tests of SNCA ([https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=6622\[geneid\]](https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=6622[geneid]))

Scientific Articles on PubMed

- PubMed (<https://pubmed.ncbi.nlm.nih.gov/?term=%28%28SNCA%5BTIAB%5D%29+OR+%28alpha-synuclein%5BTIAB%5D%29%29+AND+%28%28Genes%5BMH%5D%29+OR+%28Genetic+Phenomena%5BMH%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+360+days%22%5Bdp%5D%29%29%29>)

Catalog of Genes and Diseases from OMIM

- SYNUCLEIN, ALPHA; SNCA (<https://omim.org/entry/163890>)

Gene and Variant Databases

- NCBI Gene (<https://www.ncbi.nlm.nih.gov/gene/6622>)
- ClinVar ([https://www.ncbi.nlm.nih.gov/clinvar?term=SNCA\[gene\]](https://www.ncbi.nlm.nih.gov/clinvar?term=SNCA[gene]))

References

- Bonini NM, Giasson BI. Snaring the function of alpha-synuclein. Cell. 2005 Nov4; 123(3):359-61. doi: 10.1016/j.cell.2005.10.017. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/163890/>)

ncbi.nlm.nih.gov/16269324)

- Federoff M, Schottlaender LV, Houlden H, Singleton A. Multiple system atrophy: the application of genetics in understanding etiology. *Clin Auton Res*. 2015 Feb;25(1):19-36. doi: 10.1007/s10286-014-0267-5. Epub 2015 Feb 17. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/25687905>)
- Norris EH, Giasson BI, Lee VM. Alpha-synuclein: normal function and role in neurodegenerative diseases. *Curr Top Dev Biol*. 2004;60:17-54. doi:10.1016/S0070-2153(04)60002-0. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/15094295>)
- Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. *Hum Mutat*. 2010 Jul;31(7):763-80. doi:10.1002/humu.21277. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/20506312>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056147/>)
- Puschmann A, Bhidayasiri R, Weiner WJ. Synucleinopathies from bench to bedside. *Parkinsonism Relat Disord*. 2012 Jan;18 Suppl 1:S24-7. doi:10.1016/S1353-8020(11)70010-4. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/22166445>)
- Rosborough K, Patel N, Kalia LV. alpha-Synuclein and Parkinsonism: Updates and Future Perspectives. *Curr Neurol Neurosci Rep*. 2017 Apr;17(4):31. doi:10.1007/s11910-017-0737-y. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/28324300>)
- Scholz SW, Houlden H, Schulte C, Sharma M, Li A, Berg D, Melchers A, Paudel R, Gibbs JR, Simon-Sanchez J, Paisan-Ruiz C, Bras J, Ding J, Chen H, Traynor BJ, Arepalli S, Zonozi RR, Revesz T, Holton J, Wood N, Lees A, Oertel W, Wullner U, Goldwurm S, Pellecchia MT, Illig T, Riess O, Fernandez HH, Rodriguez RL, Okun MS, Poewe W, Wenning GK, Hardy JA, Singleton AB, Del Sorbo F, Schneider S, Bhatia KP, Gasser T. SNCA variants are associated with increased risk for multiple system atrophy. *Ann Neurol*. 2009 May;65(5):610-4. doi: 10.1002/ana.21685. Erratum In: *Ann Neurol*. 2010 Feb;67(2):277. Del Sorbo, Francesca [added]; Schneider, Susanne [added]; Bhatia, Kailash P [added]. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/19475667>) or Free article on PubMed Central (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520128/>)
- Sidhu A, Wersinger C, Vernier P. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. *FEBS Lett*. 2004 May 7;565(1-3):1-5. doi: 10.1016/j.febslet.2004.03.063. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/15135042>)
- Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of alpha-synuclein in neurological disorders. *Lancet Neurol*. 2011 Nov;10(11):1015-25. doi: 10.1016/S1474-4422(11)70213-7. Erratum In: *Lancet Neurol*. 2011 Dec;10(12):1041. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/22014436>)
- Yun JY, Lee WW, Lee JY, Kim HJ, Park SS, Jeon BS. SNCA variants and multiple system atrophy. *Ann Neurol*. 2010 Apr;67(4):554-5. doi: 10.1002/ana.21889. No abstract available. Citation on PubMed (<https://pubmed.ncbi.nlm.nih.gov/20437598>)

Genomic Location

The *SNCA* gene is found on chromosome 4 (<https://medlineplus.gov/genetics/chromosome/4/>).

Last updated March 29, 2021